World journal of methodology最新文献

{"title":"Anticoagulant use before COVID-19 diagnosis prevent COVID-19 associated acute venous thromboembolism or not: A systematic review and meta-analysis.","authors":"Kinza Iqbal, Akshat Banga, Taha Bin Arif, Sawai Singh Rathore, Abhishek Bhurwal, Syeda Kisa Batool Naqvi, Muhammad Mehdi, Pankaj Kumar, Mitali Madhu Salklan, Ayman Iqbal, Jawad Ahmed, Nikhil Sharma, Amos Lal, Rahul Kashyap, Vikas Bansal, Juan Pablo Domecq","doi":"10.5662/wjm.v14.i3.92983","DOIUrl":"10.5662/wjm.v14.i3.92983","url":null,"abstract":"<p><strong>Background: </strong>Coagulopathy and thromboembolic events are associated with poor outcomes in coronavirus disease 2019 (COVID-19) patients. There is conflicting evidence on the effects of chronic anticoagulation on mortality and severity of COVID-19 disease.</p><p><strong>Aim: </strong>To summarize the body of evidence on the effects of pre-hospital anticoagulation on outcomes in COVID-19 patients.</p><p><strong>Methods: </strong>A Literature search was performed on LitCovid PubMed, WHO, and Scopus databases from inception (December 2019) till June 2023 for original studies reporting an association between prior use of anticoagulants and patient outcomes in adults with COVID-19. The primary outcome was the risk of thromboembolic events in COVID-19 patients taking anticoagulants. Secondary outcomes included COVID-19 disease severity, in terms of intensive care unit admission or invasive mechanical ventilation/intubation requirement in patients hospitalized with COVID-19 infection, and mortality. The random effects models were used to calculate crude and adjusted odds ratios (aORs) with 95% confidence intervals (95%CIs).</p><p><strong>Results: </strong>Forty-six observational studies met our inclusion criteria. The unadjusted analysis found no association between prior anticoagulation and thromboembolic event risk [<i>n</i> = 43851, 9 studies, odds ratio (OR)= 0.67 (0.22, 2.07); <i>P</i> = 0.49; <i>I</i> ² = 95%]. The association between prior anticoagulation and disease severity was non-significant [<i>n</i> = 186782; 22 studies, OR = 1.08 (0.78, 1.49); <i>P</i> = 0.64; <i>I</i> ² = 89%]. However, pre-hospital anticoagulation significantly increased all-cause mortality risk [<i>n</i> = 207292; 35 studies, OR = 1.72 (1.37, 2.17); <i>P</i> < 0.00001; <i>I</i> ² = 93%]. Pooling adjusted estimates revealed a statistically non-significant association between pre-hospital anticoagulation and thromboembolic event risk [aOR = 0.87 (0.42, 1.80); <i>P</i> = 0.71], mortality [aOR = 0.94 (0.84, 1.05); <i>P</i> = 0.31], and disease severity [aOR = 0.96 (0.72, 1.26); <i>P</i> = 0.76].</p><p><strong>Conclusion: </strong>Prehospital anticoagulation was not significantly associated with reduced risk of thromboembolic events, improved survival, and lower disease severity in COVID-19 patients.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 mutations: An overview.","authors":"Malay Sarkar, Irappa Madabhavi","doi":"10.5662/wjm.v14.i3.89761","DOIUrl":"10.5662/wjm.v14.i3.89761","url":null,"abstract":"<p><p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to the genus Beta coronavirus and the family of Coronaviridae. It is a positive-sense, non-segmented single-strand RNA virus. Four common types of human coronaviruses circulate globally, particularly in the fall and winter seasons. They are responsible for 10%-30% of all mild upper respiratory tract infections in adults. These are 229E, NL63 of the Alfacoronaviridae family, OC43, and HKU1 of the Betacoronaviridae family. However, there are three highly pathogenic human coronaviruses: SARS-CoV-2, Middle East respiratory syndrome coronavirus, and the latest pandemic caused by the SARS-CoV-2 infection. All viruses, including SARS-CoV-2, have the inherent tendency to evolve. SARS-CoV-2 is still evolving in humans. Additionally, due to the development of herd immunity, prior infection, use of medication, vaccination, and antibodies, the viruses are facing immune pressure. During the replication process and due to immune pressure, the virus may undergo mutations. Several SARS-CoV-2 variants, including the variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617/B.1.617.2 (Delta), P.1 (Gamma), and B.1.1.529 (Omicron) have been reported from various parts of the world. These VOCs contain several important mutations; some of them are on the spike proteins. These mutations may lead to enhanced infectivity, transmissibility, and decreased neutralization efficacy by monoclonal antibodies, convalescent sera, or vaccines. Mutations may also lead to a failure of detection by molecular diagnostic tests, leading to a delayed diagnosis, increased community spread, and delayed treatment. We searched PubMed, EMBASE, Covariant, the Stanford variant Database, and the CINAHL from December 2019 to February 2023 using the following search terms: VOC, SARS-CoV-2, Omicron, mutations in SARS-CoV-2, <i>etc.</i> This review discusses the various mutations and their impact on infectivity, transmissibility, and neutralization efficacy.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Botulinum toxin type A for treating chronic low back pain: A double blinded randomized control study.","authors":"Mantu Jain, Shahnawaz Khan, Paulson Varghese, Sujit Kumar Tripathy, Manaswini Mangaraj","doi":"10.5662/wjm.v14.i3.93854","DOIUrl":"10.5662/wjm.v14.i3.93854","url":null,"abstract":"<p><strong>Background: </strong>Low back pain (LBP) is a prevalent issue that orthopedic surgeons frequently address in the outpatient setting. LBP can arise from various causes, with stiffness in the paraspinal muscles being a notable contributor. The administration of Botulinum toxin type A (BoNT-A) has been found to alleviate back pain by relaxing these stiff muscles. While BoNT-A is approved for use in numerous conditions, a limited number of randomized clinical trials (RCTs) validate its efficacy specifically for treating LBP.</p><p><strong>Aim: </strong>To study the safety and the efficacy of BoNT-A in minimizing pain and improving functional outcomes in patients of chronic LBP (CLBP).</p><p><strong>Methods: </strong>In this RCT, adults aged 18-60 years with mechanical LBP persisting for at least six months were enrolled. Participants were allocated to either the Drug group, receiving 200 Ipsen Units (2 mL) of BoNT-A, or the Control group, which received a 2 mL placebo. Over a 2-month follow-up period, both groups were assessed using the Visual Analog Scale (VAS) for pain intensity and the Oswestry Disability Index (ODI) for disability at the start and conclusion of the study. A decrease in pain by 50% was deemed clinically significant.</p><p><strong>Results: </strong>The study followed 40 patients for two months, with 20 in each group. A clinically significant reduction in pain was observed in 36 participants. There was a statistically significant decrease in both VAS and ODI scores in the groups at the end of two months. Nonetheless, when comparing the mean score changes, only the reduction in ODI scores (15 in the placebo group <i>vs</i> 16.5 in the drug group, clinically insignificant) was statistically significant (<i>P</i> = 0.012), whereas the change in mean VAS scores was not significant (<i>P</i> = 0.45).</p><p><strong>Conclusion: </strong>The study concludes that BoNT-A does not offer a short-term advantage over placebo in reducing pain or improving LBP scores in CLBP patients.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Method \"Monte Carlo\" in healthcare.","authors":"Tsvetelina Velikova, Niya Mileva, Emilia Naseva","doi":"10.5662/wjm.v14.i3.93930","DOIUrl":"10.5662/wjm.v14.i3.93930","url":null,"abstract":"<p><p>In public health, simulation modeling stands as an invaluable asset, enabling the evaluation of new systems without their physical implementation, experimentation with existing systems without operational adjustments, and testing system limits without real-world repercussions. In simulation modeling, the Monte Carlo method emerges as a powerful yet underutilized tool. Although the Monte Carlo method has not yet gained widespread prominence in healthcare, its technological capabilities hold promise for substantial cost reduction and risk mitigation. In this review article, we aimed to explore the transformative potential of the Monte Carlo method in healthcare contexts. We underscore the significance of experiential insights derived from simulated experimentation, especially in resource-constrained scenarios where time, financial constraints, and limited resources necessitate innovative and efficient approaches. As public health faces increasing challenges, incorporating the Monte Carlo method presents an opportunity for enhanced system construction, analysis, and evaluation.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinoscopes: Past and present.","authors":"Mutali Musa, Ehimare Enaholo, Babatunde Ismail Bale, Carlo Salati, Leopoldo Spadea, Marco Zeppieri","doi":"10.5662/wjm.v14.i3.91497","DOIUrl":"10.5662/wjm.v14.i3.91497","url":null,"abstract":"<p><strong>Background: </strong>Retinoscopy is arguably the most important method in the eye clinic for diagnosing and managing refractive errors. Advantages of retinoscopy include its non-invasive nature, ability to assess patients of all ages, and usefulness in patients with limited cooperation or communication skills.</p><p><strong>Aim: </strong>To discuss the history of retinoscopes and examine current literature on the subject.</p><p><strong>Methods: </strong>A search was conducted on the PubMed and with the reference citation analysis (https://www.referencecitationanalysis.com) database using the term \"Retinoscopy,\" with a range restricted to the last 10 years (2013-2023). The search string algorithm was: \"Retinoscopy\" (MeSH Terms) OR \"Retinoscopy\" (All Fields) OR \"Retinoscopes\" (All Fields) AND [(All Fields) AND 2013: 2023 (pdat)].</p><p><strong>Results: </strong>This systematic review included a total of 286 records. Publications reviewed iterations of the retinoscope into autorefractors, infrared photo retinoscope, television retinoscopy, and the Wifi enabled digital retinoscope.</p><p><strong>Conclusion: </strong>The retinoscope has evolved significantly since its discovery, with a significant improvement in its diagnostic capabilities. While it has advantages such as non-invasiveness and broad applicability, limitations exist, and the need for skilled interpretation remains. With ongoing research, including the integration of artificial intelligence, retinoscopy is expected to continue advancing and playing a vital role in eye care.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stent A pancreaticojejunostomy after pancreatoduodenectomy: Is it always necessary?","authors":"Dimitrios Symeonidis, Dimitris Zacharoulis, Georgios Tzovaras, Labrini Kissa, Athina A Samara, Eleana Petsa, Konstantinos Tepetes","doi":"10.5662/wjm.v14.i3.90164","DOIUrl":"10.5662/wjm.v14.i3.90164","url":null,"abstract":"<p><p>The establishment of a postoperative pancreatic fistula (POPF) is considered the most common and, concomitantly, the most serious complication associated with pancreaticoduodenectomy (PD). The search for either technical modifications of the operative technique or pharmaceutical interventions that could possibly aid in decreasing the incidence of this often-devastating complication appears justified. The stenting of the pancreatic duct, with the use of either internal or external stents, has been evaluated in this direction. In theory, it is an approach that could eliminate many pathophysiological factors responsible for the occurrence of a POPF. The purpose of the present study was to review the current data regarding the role of pancreatic duct stenting on the incidence of POPF, after PD, by using PubMed and Reference Citation Analysis. In general, previous studies seem to highlight the superiority of external stents over their internal counterparts in regard to the incidence of POPF; this is at the cost, however, of increased morbidity associated mainly with the stent removal. Certainly, the use of an internal stent is a less invasive approach with acceptable results and is definitely deprived of the drawbacks arising through the complete diversion of pancreatic juice from the gastrointestinal tract. Bearing in mind the scarcity of high-quality data on the subject, an approach of reserving stent placement for the high-risk for POPF patients and individualizing the selection between the use of an internal or an external stent according to the distinct characteristics of each individual case scenario appears appropriate.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early versus delayed necrosectomy in pancreatic necrosis: A population-based cohort study on readmission, healthcare utilization, and in-hospital mortality.","authors":"Hassam Ali, Faisal Inayat, Vinay Jahagirdar, Fouad Jaber, Arslan Afzal, Pratik Patel, Hamza Tahir, Muhammad Sajeel Anwar, Attiq Ur Rehman, Muhammad Sarfraz, Ahtshamullah Chaudhry, Gul Nawaz, Dushyant Singh Dahiya, Amir H Sohail, Muhammad Aziz","doi":"10.5662/wjm.v14.i3.91810","DOIUrl":"10.5662/wjm.v14.i3.91810","url":null,"abstract":"<p><strong>Background: </strong>Acute necrotizing pancreatitis is a severe and life-threatening condition. It poses a considerable challenge for clinicians due to its complex nature and the high risk of complications. Several minimally invasive and open necrosectomy procedures have been developed. Despite advancements in treatment modalities, the optimal timing to perform necrosectomy lacks consensus.</p><p><strong>Aim: </strong>To evaluate the impact of necrosectomy timing on patients with pancreatic necrosis in the United States.</p><p><strong>Methods: </strong>A national retrospective cohort study was conducted using the 2016-2019 Nationwide Readmissions Database. Patients with non-elective admissions for pancreatic necrosis were identified. The participants were divided into two groups based on the necrosectomy timing: The early group received intervention within 48 hours, whereas the delayed group underwent the procedure after 48 hours. The various intervention techniques included endoscopic, percutaneous, or surgical necrosectomy. The major outcomes of interest were 30-day readmission rates, healthcare utilization, and inpatient mortality.</p><p><strong>Results: </strong>A total of 1309 patients with pancreatic necrosis were included. After propensity score matching, 349 cases treated with early necrosectomy were matched to 375 controls who received delayed intervention. The early cohort had a 30-day readmission rate of 8.6% compared to 4.8% in the delayed cohort (<i>P</i> = 0.040). Early necrosectomy had lower rates of mechanical ventilation (2.9% <i>vs</i> 10.9%, <i>P</i> < 0.001), septic shock (8% <i>vs</i> 19.5%, <i>P</i> < 0.001), and in-hospital mortality (1.1% <i>vs</i> 4.3%, <i>P</i> = 0.01). Patients in the early intervention group incurred lower healthcare costs, with median total charges of $52202 compared to $147418 in the delayed group. Participants in the early cohort also had a relatively shorter median length of stay (6 <i>vs</i> 16 days, <i>P</i> < 0.001). The timing of necrosectomy did not significantly influence the risk of 30-day readmission, with a hazard ratio of 0.56 (95% confidence interval: 0.31-1.02, <i>P</i> = 0.06).</p><p><strong>Conclusion: </strong>Our findings show that early necrosectomy is associated with better clinical outcomes and lower healthcare costs. Delayed intervention does not significantly alter the risk of 30-day readmission.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide for the management of diabesity: The real-world experience.","authors":"Mohammed Alkhalifah, Hafsa Afsar, Anindya Shams, Dania Blaibel, Vishnu Chandrabalan, Joseph M Pappachan","doi":"10.5662/wjm.v14.i3.91832","DOIUrl":"10.5662/wjm.v14.i3.91832","url":null,"abstract":"<p><strong>Background: </strong>Diabesity (diabetes as a consequence of obesity) has emerged as a huge healthcare challenge across the globe due to the obesity pandemic. Judicious use of antidiabetic medications including semaglutide is important for optimal management of diabesity as proven by multiple randomized controlled trials. However, more real-world data is needed to further improve the clinical practice.</p><p><strong>Aim: </strong>To study the real-world benefits and side effects of using semaglutide to manage patients with diabesity.</p><p><strong>Methods: </strong>We evaluated the efficacy and safety of semaglutide use in managing patients with diabesity in a large academic hospital in the United States. Several parameters were analyzed including demographic information, the data on improvement of glycated hemoglobin (HbA1c), body weight reduction and insulin dose adjustments at 6 and 12 months, as well as at the latest follow up period. The data was obtained from the electronic patient records between January 2019 to May 2023.</p><p><strong>Results: </strong>106 patients (56 males) with type 2 diabetes mellitus (T2DM), mean age 60.8 ± 11.2 years, mean durations of T2DM 12.4 ± 7.2 years and mean semaglutide treatment for 2.6 ± 1.1 years were included. Semaglutide treatment was associated with significant improvement in diabesity outcomes such as mean weight reductions from baseline 110.4 ± 24.6 kg to 99.9 ± 24.9 kg at 12 months and 96.8 ± 22.9 kg at latest follow up and HbA1c improvement from baseline of 82 ± 21 mmol/mol to 67 ± 20 at 12 months and 71 ± 23 mmol/mol at the latest follow up. An insulin dose reduction from mean baseline of 95 ± 74 units to 76.5 ± 56.2 units was also observed at the latest follow up. Side effects were mild and mainly gastrointestinal like bloating and nausea improving with prolonged use of semaglutide.</p><p><strong>Conclusion: </strong>Semaglutide treatment is associated with significant improvement in diabesity outcomes such as reduction in body weight, HbA1c and insulin doses without major adverse effects. Reviews of largescale real-world data are expected to inform better clinical practice decision making to improve the care of patients with diabesity.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Violence study of healthcare workers and systems in the Caribbean: ViSHWaS-Caribbean study.","authors":"Reshon Hadmon, Daniella Myriam Pierre, Akshat Banga, Jacques W Clerville, Hans Mautong, Precious Akinsanya, Rajat Das Gupta, Sama Soliman, Tolupe M Hunjah, Bamidele A Hunjah, Hafeez Hamza, Ruman Khurshid Qasba, Faisal A Nawaz, Salim Surani, Rahul Kashyap","doi":"10.5662/wjm.v14.i3.92932","DOIUrl":"10.5662/wjm.v14.i3.92932","url":null,"abstract":"<p><strong>Background: </strong>Violence against healthcare workers (HCWs) in the Caribbean continues to prevail yet remains underreported. Our aim is to determine the cause, traits, and consequences of violence on HCWs in the Caribbean.</p><p><strong>Aim: </strong>To determine the cause, traits, and consequences of violence on HCWs in the Caribbean.</p><p><strong>Methods: </strong>This research adopted an online cross-sectional survey approach, spanning over eight weeks (between June 6^th and August 9^th, 2022). The survey was generated using Research Electronic Data Capture forms and followed a snowballing strategy to contact individuals using emails, social media, text messages, <i>etc.</i> Logistic regression analysis was performed to evaluate the variables that influence violence, including gender, age, years of experience, institution type, and night shift frequency.</p><p><strong>Results: </strong>The survey was completed by 225 HCWs. Females comprised 61%. Over 51% of respondents belonged to the 21 to 35 age group. Dominica (<i>n</i> = 61), Haiti (<i>n</i> = 50), and Grenada (<i>n</i> = 31) had the most responses. Most HCWs (49%) worked for government academic institutions, followed by community hospitals (23%). Medical students (32%), followed by attending physicians (22%), and others (16%) comprised the most common cadre of respondents. About 39% of the participants reported experiencing violence themselves, and 18% reported violence against colleague(s). Verbal violence (48%), emotional abuse (24%), and physical misconduct (14%) were the most common types of violence. Nearly 63% of respondents identified patients or their relatives as the most frequent aggressors. Univariate logistic regression analyses demonstrated that female gender (OR = 2.08; 95%CI: 1.16-3.76, <i>P</i> = 0.014) and higher frequency of night shifts (OR = 2.22; 95%CI: 1.08-4.58, <i>P</i> = 0.030) were associated with significantly higher odds of experiencing violence. More than 50% of HCWs felt less motivated and had decreased job satisfaction post-violent conduct.</p><p><strong>Conclusion: </strong>A large proportion of HCWS in the Caribbean are exposed to violence, yet the phenomenon remains underreported. As a result, HCWs' job satisfaction has diminished.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensemble for evaluating diagnostic efficacy of non-invasive indices in predicting liver fibrosis in untreated hepatitis C virus population.","authors":"Navneet Kaur, Gitanjali Goyal, Ravinder Garg, Chaitanya Tapasvi, Umit Demirbaga","doi":"10.5662/wjm.v14.i3.91058","DOIUrl":"10.5662/wjm.v14.i3.91058","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis C virus (HCV) infection progresses through various phases, starting with inflammation and ending with hepatocellular carcinoma. There are several invasive and non-invasive methods to diagnose chronic HCV infection. The invasive methods have their benefits but are linked to morbidity and complications. Thus, it is important to analyze the potential of non-invasive methods as an alternative. Shear wave elastography (SWE) is a non-invasive imaging tool widely validated in clinical and research studies as a surrogate marker of liver fibrosis. Liver fibrosis determination by invasive liver biopsy and non-invasive SWE agree closely in clinical studies and therefore both are gold standards.</p><p><strong>Aim: </strong>To analyzed the diagnostic efficacy of non-invasive indices [serum fibronectin, aspartate aminotransferase to platelet ratio index (APRI), alanine aminotransferase ratio (AAR), and fibrosis-4 (FIB-4)] in relation to SWE. We have used an Artificial Intelligence method to predict the severity of liver fibrosis and uncover the complex relationship between non-invasive indices and fibrosis severity.</p><p><strong>Methods: </strong>We have conducted a hospital-based study considering 100 untreated patients detected as HCV positive using a quantitative Real-Time Polymerase Chain Reaction assay. We performed statistical and probabilistic analyses to determine the relationship between non-invasive indices and the severity of fibrosis. We also used standard diagnostic methods to measure the diagnostic accuracy for all the subjects.</p><p><strong>Results: </strong>The results of our study showed that fibronectin is a highly accurate diagnostic tool for predicting fibrosis stages (mild, moderate, and severe). This was based on its sensitivity (100%, 92.2%, 96.2%), specificity (96%, 100%, 98.6%), Youden's index (0.960, 0.922, 0.948), area under receiver operating characteristic curve (0.999, 0.993, 0.922), and Likelihood test (LR+ > 10 and LR- < 0.1). Additionally, our Bayesian Network analysis revealed that fibronectin (> 200), AAR (> 1), APRI (> 3), and FIB-4 (> 4) were all strongly associated with patients who had severe fibrosis, with a 100% probability.</p><p><strong>Conclusion: </strong>We have found a strong correlation between fibronectin and liver fibrosis progression in HCV patients. Additionally, we observed that the severity of liver fibrosis increases with an increase in the non-invasive indices that we investigated.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}